Vivien Andrea Sheehan, MD, PhD

Location

  • Texas Medical Center

Specialty

Blood Disorders

Phone: 832-822-4459
Fax: 832-825-1453

Contact Information

1102 Bates Street
Suite 1030.02
Houston, TX 77030
United States
Texas

Research Laboratory

Research Area

  • Hematology
  • Sickle Cell Disease

Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

Education

School Education Degree Year
Baylor College of Medicine fellowship Pediatric Hematology Oncology 2012
St. Jude Children's Research Hospital fellowship Pediatric Hematology Oncology 2011
University of Tennessee Health Science Center fellowship Internal Medicine 2011
University of Cincinnati College of Medicine residency Pediatrics 2008
Emory University School of Medicine medical school Medical Student 2004
Texas A & M University - College Station postgraduate education Doctor of Philosophy 2000

About

Dr. Vivien Sheehan is a pediatric and adult hematologist specializing in sickle cell disease (SCD). Her clinical interests include: sickle cell disease, the treatment of hemoglobin in patients with sickle cell disease, and transitioning chronically ill pediatric patients to adult subspecialty care. Dr. Vivien Sheehan is a member of the Sickle Cell Program in the Hematology Center at Texas Children's Hospital. She is board certified in internal medicine, pediatrics, IM hematology, and pediatric hematology/oncology.

Organization

Organization Name Role
American Society for Human Genetics (ASHG) Member
American Academy of Pediatrics (AAP) Member
American College of Physicians (ACP) Member
American Society of Hematology (ASH) Member

Research Statement

Dr. Vivien Sheehan is a pediatric and adult hematologist specializing in sickle cell disease (SCD). Her research projects range from clinical research to basic science.

In 2018, she assisted in the design of the American Society of Hematology Sickle Cell Disease Clinical Trial Network, which is focused on advancing development of new and more effective therapeutics for individuals with sickle cell disease. She was invited to be one of four members of the oversight committee that will identify, recruit and evaluate sites and interface with industry and federal agencies to promote this Network.

Selected Publications